Search

Your search keyword '"Álvarez-Larrán, Alberto"' showing total 6 results
Start Over Author "Álvarez-Larrán, Alberto" Publisher elsevier b.v.
6 results on '"Álvarez-Larrán, Alberto"'

2. AS088 - Natural history of polycytemia vera and essential thrombocythemia presenting with splanchnic vein thrombosis.

Author

Magaz, Marta, Álvarez-Larrán, Alberto, Pereira, Arturo, Turon, Fanny, Hernández-Boluda, Juan Carlos, Alvarado, Edilmar, de Riba, Bea, Alvarez-Navascues, Mari Carmen, Luis, Tellez, Puente, Angela, Fortea, Jose Ignacio, Diaz, Raquel, Romero-Gutiérrez, Marta, González-Alayón, Carlos, Llop, Elba, Ferreira, Carlos Noronha, Ferrusquia, José, Baiges, Anna, Calleja Panero, José Luis, and Crespo, Javier

Subjects
*NATURAL history, *THROMBOSIS, *VEINS
Published
2020
Full Text
View/download PDF

5. Intermediate dose of nonpegylated liposomal doxorubicin combination (R-CMyOP) as first line chemotherapy for frail elderly patients with aggressive lymphoma

Author

Gimeno, Eva, Sánchez-González, Blanca, Álvarez-Larrán, Alberto, Pedro, Carmen, Abella, Eugenia, Comín, Josep, Saumell, Silvia, García-Pallarols, Francesc, Gómez, Miquel, Besses, Carles, and Salar, Antonio

Subjects
*DRUG efficacy, *LYMPHOMA treatment, *DOXORUBICIN, *DRUG dosage, *DRUG therapy, *FRAIL elderly, *COMORBIDITY, *RITUXIMAB, *COHORT analysis
Abstract

Abstract: Doxorubicin-containing chemotherapy is the standard regimen for elderly patients with aggressive lymphoma. However, many of them cannot receive it due to severe associated comorbidities. Toxicity and efficacy of intermediate doses of nonpegylated liposomal doxorubicin (NPLD) in modified-CHOP regimen±Rituximab were prospectively analyzed in 35 frail elderly patients (median age: 76 years) with previously untreated aggressive lymphoma with one or more severe comorbidities. NPLD at intermediate doses (30mg/m2) is effective and well tolerated in these patients. In addition, NT-proBNP levels >900ng/ml at diagnosis have demonstrated to be a good predictor for OS and PFS in this cohort of patients. [Copyright &y& Elsevier]

Published
2011
Full Text
View/download PDF

6. Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia

Author

Maffioli, Margherita, Camós, Mireia, Gaya, Anna, Hernández-Boluda, Juan-Carlos, Álvarez-Larrán, Alberto, Domingo, Abel, Granell, Miquel, Guillem, Vicent, Vallansot, Rolando, Costa, Dolors, Bellosillo, Beatriz, Colomer, Dolors, and Cervantes, Francisco

Subjects
*GENETIC polymorphisms, *CATIONS, *MULTIDRUG resistance, *IMATINIB, *MYELOID leukemia, *CHRONIC diseases, *PROTEINS, *STATISTICAL correlation, *GENES
Abstract

Abstract: The association between seven polymorphisms in the genes hOCT1 and MDR1, encoding for imatinib transporter proteins, and the response to imatinib 400mg/daily was investigated in 65 patients newly diagnosed with chronic-phase chronic myeloid leukemia. The AA genotype at the rs6935207 hOCT1 polymorphic locus was not detected in patients with inadequate response to imatinib. The CC genotype at the rs1045642 (C3435T) MDR1 locus was associated with primary failure, whereas a T allele at the rs2032582 (G2677T/A) MDR1 locus seemed to protect from primary failure. Beside, the MDR1 haplotype 1236T-2677G-3435C was more frequently found in patients primarily resistant to imatinib. [Copyright &y& Elsevier]

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results